Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Arocell AB is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that each of the 2 pending office actions is being reviewed by a different examiner in a different technical division. With 2 distinct examiners and 2 distinct art units involved, the company must manage two separate prosecution tracks simultaneously.
FONTAINHAS, AURORA M is the busiest examiner for the portfolio, currently handling 1 busiest examiner pending office action. This 1 busiest examiner pending case represents half of the company's total of 2 pending office actions. Practitioners should note that the 2 distinct art units suggest different technical focuses within the biotechnology sector. Successfully resolving the 2 pending office actions will require addressing the specific concerns of both 2 distinct examiners across their respective 2 distinct art units. The 1 busiest examiner pending matter requires a tailored response to satisfy FONTAINHAS, AURORA M. Coordination between the 2 distinct art units is necessary to ensure consistent results for the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FONTAINHAS, AURORA M | 1 | 37.8% | +49.4% |
| DUNN, MCKENZIE A | 1 | 54.2% | +57.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572370 | PREDICTING CANCER RELAPSE | FONTAINHAS, AURORA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572370 | PREDICTING CANCER RELAPSE | FONTAINHAS, AURORA M | — |
| 17794286 | PREDICTING PATIENT SURVIVAL | DUNN, MCKENZIE A | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18572370 | PREDICTING CANCER RELAPSE | FONTAINHAS, AURORA M | 1675 | §101§102§103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 17794286 | PREDICTING PATIENT SURVIVAL | DUNN, MCKENZIE A | 1678 | §103 | Non-Final OA | — | Pending | Jul 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArocell AB has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Aurora M Fontainhas has the most, with 1 of Arocell AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
